|
WO2005003100A2
(en)
|
2003-07-03 |
2005-01-13 |
Myriad Genetics, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
WO2005073224A2
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
|
WO2005070891A2
(en)
|
2004-01-23 |
2005-08-04 |
Amgen Inc |
Compounds and methods of use
|
|
MXPA06014129A
(es)
*
|
2004-06-04 |
2007-03-07 |
Arena Pharm Inc |
Derivados de arilo y heteroarilo sustituidos como moduladores del metabolismo y profilaxis y tratamiento de trastornos relacionados con los mismos.
|
|
JP2008515956A
(ja)
*
|
2004-10-12 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
１１β−ヒドロキシステロイドデヒドロゲナーゼ１型活性スピロ化合物
|
|
ES2450566T3
(es)
|
2004-11-30 |
2014-03-25 |
Amgen Inc. |
Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
|
|
US20060167044A1
(en)
*
|
2004-12-20 |
2006-07-27 |
Arnaiz Damian O |
Piperidine derivatives and their use as anti-inflammatory agents
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
US7709516B2
(en)
*
|
2005-06-17 |
2010-05-04 |
Endorecherche, Inc. |
Helix 12 directed non-steroidal antiandrogens
|
|
JP2009514818A
(ja)
*
|
2005-11-01 |
2009-04-09 |
ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー |
置換アミドの製薬学的用途
|
|
CA2627307A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Transtech Pharma, Inc. |
Pharmaceutical use of substituted amides
|
|
JP2009522295A
(ja)
*
|
2005-12-30 |
2009-06-11 |
アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド |
置換ビス−アミドメタロプロテアーゼ阻害剤
|
|
TW200804347A
(en)
*
|
2006-01-10 |
2008-01-16 |
Janssen Pharmaceutica Nv |
Urotensin II receptor antagonists
|
|
CA2646588A1
(en)
*
|
2006-03-21 |
2007-09-27 |
High Point Pharmaceuticals, Llc |
Adamantane derivatives for the treatment of the metabolic syndrome
|
|
EP2010479A1
(en)
|
2006-04-07 |
2009-01-07 |
High Point Pharmaceuticals, LLC |
11 beta-hydroxysteroid dehydrogenase type 1 active compounds
|
|
EP2038255A2
(en)
*
|
2006-06-16 |
2009-03-25 |
High Point Pharmaceuticals, LLC |
Pharmaceutical use of substituted piperidine carboxamides
|
|
EP1878721A1
(en)
*
|
2006-07-13 |
2008-01-16 |
Novo Nordisk A/S |
4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
|
|
WO2008006702A1
(en)
*
|
2006-07-13 |
2008-01-17 |
High Point Pharmaceuticals, Llc. |
11beta-hydroxysteroid dehydrogenase type 1 active compounds
|
|
CL2007002097A1
(es)
*
|
2006-07-20 |
2008-01-18 |
Smithkline Beecham Corp |
Compuestos derivados de pirrolidina o morfolina antagonistas de urotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar insuficiencia cardiaca congestiva, insuficiencia cardiaca isquemica, angina, isquemia del miocardio, vejiga hiperactiva, asma y/o copd, entre otras.
|
|
WO2008016534A1
(en)
|
2006-07-31 |
2008-02-07 |
Janssen Pharmaceutica, N.V. |
Urotensin ii receptor antagonists
|
|
FR2904827B1
(fr)
*
|
2006-08-11 |
2008-09-19 |
Sanofi Aventis Sa |
Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
|
|
EP2091944B1
(en)
|
2006-11-17 |
2011-05-18 |
Pfizer Inc. |
Substituted bicyclocarboxyamide compounds
|
|
WO2008101885A1
(en)
*
|
2007-02-23 |
2008-08-28 |
High Point Pharmaceuticals, Llc |
N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
|
|
EP2125704A1
(en)
*
|
2007-02-23 |
2009-12-02 |
High Point Pharmaceuticals, LLC |
N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
|
|
JP2010519242A
(ja)
*
|
2007-02-23 |
2010-06-03 |
ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー |
新規化合物
|
|
WO2008101914A2
(en)
*
|
2007-02-23 |
2008-08-28 |
High Point Pharmaceuticals, Llc |
N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
|
|
KR20100015414A
(ko)
*
|
2007-03-09 |
2010-02-12 |
하이 포인트 파마슈티칼스, 엘엘씨 |
히드록시스테로이드 탈수소효소 억제제로서 인돌- 및 벤즈이미다졸 아미드
|
|
JP2010522766A
(ja)
*
|
2007-03-28 |
2010-07-08 |
ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー |
１１ベータ−ｈｓｄ１活性化合物
|
|
EP2152081B1
(en)
*
|
2007-04-11 |
2012-10-24 |
High Point Pharmaceuticals, LLC |
Novel compounds
|
|
JP2010526777A
(ja)
*
|
2007-04-24 |
2010-08-05 |
ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー |
置換アミドの医薬用途
|
|
PA8782701A1
(es)
|
2007-06-07 |
2009-01-23 |
Janssen Pharmaceutica Nv |
Antagonistas del receptor de urotensina ii
|
|
WO2008156828A2
(en)
*
|
2007-06-20 |
2008-12-24 |
Vitae Pharmaceuticals, Inc. |
Renin inhibitors
|
|
JP5343082B2
(ja)
*
|
2007-10-29 |
2013-11-13 |
アムジエン・インコーポレーテツド |
ベンゾモルホリン誘導体および使用方法
|
|
WO2009063364A2
(en)
*
|
2007-11-13 |
2009-05-22 |
Encysive Pharmaceuticals Inc. |
Modulators of urotensin receptor and methods of use thereof
|
|
FR2927330B1
(fr)
*
|
2008-02-07 |
2010-02-19 |
Sanofi Aventis |
Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
ES2379762T3
(es)
|
2008-08-02 |
2012-05-03 |
Janssen Pharmaceutica N.V. |
Antagonistas del receptor de la urotensina II
|
|
WO2012058133A1
(en)
*
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
Isoindolinone pde10 inhibitors
|
|
CN102060811A
(zh)
*
|
2011-01-19 |
2011-05-18 |
山西大学 |
单磺酰哌嗪的合成方法
|
|
JP2016505002A
(ja)
|
2012-12-21 |
2016-02-18 |
エピザイム，インコーポレイティド |
ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
|
|
JP2016505000A
(ja)
|
2012-12-21 |
2016-02-18 |
エピザイム，インコーポレイティド |
Ｐｒｍｔ５阻害剤およびその使用
|
|
CA2894230A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Methods of inhibiting prmt5
|
|
MY199894A
(en)
|
2012-12-21 |
2023-11-27 |
Epizyme Inc |
Prmt5 inhibitors and uses thereof
|
|
WO2014100716A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CA2894157A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP2970266B1
(en)
|
2013-03-15 |
2018-01-31 |
Epizyme, Inc. |
1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
|
|
KR20160003647A
(ko)
|
2013-03-15 |
2016-01-11 |
에피자임, 인코포레이티드 |
Carm1 억제제 및 이의 용도
|
|
DK3054936T5
(da)
|
2013-10-10 |
2024-03-18 |
Eastern Virginia Medical School |
4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer
|
|
JP6272604B2
(ja)
*
|
2013-12-27 |
2018-01-31 |
日本サプリメント株式会社 |
糖取り込み促進剤
|
|
KR20160106627A
(ko)
*
|
2013-12-30 |
2016-09-12 |
라이프에스씨아이 파마슈티컬스, 인크. |
치료적 억제 화합물
|
|
CA2953572A1
(en)
|
2014-08-04 |
2016-02-11 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
|
SG10201902963PA
(en)
|
2014-10-06 |
2019-05-30 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
US10752588B2
(en)
|
2014-12-19 |
2020-08-25 |
The Broad Institute, Inc. |
Dopamine D2 receptor ligands
|
|
US10633336B2
(en)
|
2014-12-19 |
2020-04-28 |
The Broad Institute, Inc. |
Dopamine D2 receptor ligands
|
|
AU2017240685B2
(en)
|
2016-03-31 |
2021-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP3241874B1
(en)
|
2016-05-04 |
2019-08-14 |
Agfa Nv |
Acylphosphine oxide photoinitiators
|
|
GEP20217329B
(en)
|
2016-09-30 |
2021-12-10 |
Vertex Pharma |
Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
|
HUE052205T2
(hu)
|
2016-12-09 |
2021-04-28 |
Vertex Pharma |
Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására
|
|
PT3562821T
(pt)
|
2016-12-28 |
2021-03-03 |
Minoryx Therapeutics S L |
Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade
|
|
JP7017797B2
(ja)
*
|
2017-02-24 |
2022-02-09 |
深▲チェン▼市霊蘭生物医薬科技有限公司 |
新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用
|
|
BR112019025801A2
(pt)
|
2017-06-08 |
2020-07-07 |
Vertex Pharmaceuticals Incorporated |
métodos de tratamento para fibrose cística
|
|
BR112020000941A2
(pt)
|
2017-07-17 |
2020-07-21 |
Vertex Pharmaceuticals Incorporated |
métodos de tratamento para fibrose cística
|
|
US11434201B2
(en)
|
2017-08-02 |
2022-09-06 |
Vertex Pharmaceuticals Incorporated |
Processes for preparing pyrrolidine compounds
|
|
CA3078893A1
(en)
|
2017-10-19 |
2019-04-25 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of cftr modulators
|
|
CA3085006A1
(en)
|
2017-12-08 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
|
EP3774825A1
(en)
|
2018-04-13 |
2021-02-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
|
CN110938021A
(zh)
*
|
2019-12-18 |
2020-03-31 |
荆门市丽康源纺织科技有限公司 |
一种染料中间体3-(β-羟乙基砜基)苯胺的制备方法
|
|
CN111170897A
(zh)
*
|
2019-12-18 |
2020-05-19 |
荆门市丽康源纺织科技有限公司 |
一种间位酯的制备方法及间位酯
|
|
MX2023003476A
(es)
*
|
2020-09-25 |
2023-06-22 |
Escient Pharmaceuticals Inc |
Moduladores del receptor x2 de proteína g relacionado con mas y productos y métodos relacionados.
|
|
CN114890946B
(zh)
*
|
2022-05-20 |
2023-10-27 |
沈阳药科大学 |
含有吗啉丙基的[(喹啉-4-基)氨基]苯甲酰胺类化合物及其制备与应用
|